<i>Journal of Gastroenterology and Hepatology</i>｜Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

doi:10.3969/j.issn.1001-5256.2023.11.gwjpwzjj1

Volume 39 Issue 11

Nov. 2023

Turn off MathJax

Article Contents

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(11): 2523-2523

PDF( 903 KB)

Journal of Gastroenterology and Hepatology｜Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

DOI: 10.3969/j.issn.1001-5256.2023.11.gwjpwzjj1

Published Date: 2023-11-28

Abstract

FullText(HTML)

References(0)

References

Relative Articles

[1]	Journal of Hepatology｜Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway[J]. Journal of Clinical Hepatology, 2025, 41(2): 364-364. doi: 10.12449/JCH2502.gwqkjpwzjj2
[2]	Journal of Hepatology｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy[J]. Journal of Clinical Hepatology, 2024, 40(11): 2237-2237. doi: 10.12449/JCH2411.gwqkjpwzjj2
[3]	Journal of Hepatology｜An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(2): 342-342. doi: 10.12449/JCH2402.gwqkjpwzjj3
[4]	Journal of Hepatology｜Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1777-1777. doi: 10.12449/JCH2409.gwqkjpwzjj2
[5]	Journal of Hepatology｜Association of food insecurity with the prevalence and liver-related mortality of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. Journal of Clinical Hepatology, 2024, 40(10): 2126-2126. doi: 10.12449/JCH2410.gwqkjpwzjj3
[6]	Journal of the American Medical Association｜Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: A randomized clinical trial[J]. Journal of Clinical Hepatology, 2024, 40(8): 1652-1652. doi: 10.12449/JCH2408.gwqkjpwzjj3
[7]	Hepatology International｜Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial[J]. Journal of Clinical Hepatology, 2023, 39(10): 2431-2431. doi: 10.3969/j.issn.1001-5256.2023.10.gwjpwzjj1
[8]	Hepatology Research｜Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1171-1171. doi: 10.3969/j.issn.1001-5256.2023.05.gwjpwzjj3
[9]	Gastroenterology｜Postprandial plasma lipidomics reveal specific alteration of hepatic-derived diacylglycerols in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1607-1607. doi: 10.3969/j.issn.1001-5256.2022.07.gwjpwzjj1
[10]	Journal of Hepatology｜PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(3): 698-698. doi: 10.3969/j.issn.1001-5256.2022.3.gwjpwzjj2
[11]	Hepatology｜Myeloid cell-specific IL-6 signal alleviates nonalcoholic fatty liver disease-related fibrosis by promoting the release of microRNA-223-enriched exosome[J]. Journal of Clinical Hepatology, 2022, 38(2): 414-414. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj6
[12]	Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(2): 401-401. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5
[13]	Zhenyang SHEN, Xiaobo CAI, Lungen LU. Application of farnesoid X receptor agonists in treatment of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1402-1405. doi: 10.3969/j.issn.1001-5256.2022.06.038
[14]	Journal of Gastroenterology and Hepatology｜A high serum ferritin level increases the risk of death associated with chronic liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(2): 438-438. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj9
[15]	Journal of Gastroenterology and Hepatology｜Rifampicin can improve cholestasis in patients with persistent hepatocellular secretory failure[J]. Journal of Clinical Hepatology, 2022, 38(2): 396-396. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj4
[16]	Zhihua ZUO, Chuyi ZENG, Yao JIANG, Hualin TAO, Yongcan GUO. Regulatory role of long non-coding RNAs in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1704-1707. doi: 10.3969/j.issn.1001-5256.2021.07.048
[17]	Shengnan DU, Jingjing GAO, Tao WANG, Yuanye JIANG, Qin CAO. Value of circular RNA in the diagnosis and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2684-2688. doi: 10.3969/j.issn.1001-5256.2021.11.043
[18]	Zhang KaiLing, Li LiangPing. Mechanism of action of intestinal farnesoid X receptor in nonalcoholic fatty liver disease and related targeted drugs[J]. Journal of Clinical Hepatology, 2020, 36(5): 1160-1163. doi: 10.3969/j.issn.1001-5256.2020.05.047
[19]	Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
[20]	Mai JingYin, Chen TianYang, Cheng Yang. Changes in microRNA expression profile in the liver of mice with nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2017, 33(12): 2372-2375. doi: 10.3969/j.issn.1001-5256.2017.12.023

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (204) PDF downloads(25)

Journal of Gastroenterology and Hepatology｜Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

DOI: 10.3969/j.issn.1001-5256.2023.11.gwjpwzjj1

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Journal of Gastroenterology and Hepatology｜Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

DOI: 10.3969/j.issn.1001-5256.2023.11.gwjpwzjj1

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content